BNGO — BioNano Genomics Balance Sheet
0.000.00%
- $18.39m
- $5.72m
- $30.78m
- 12
- 70
- 48
- 38
Annual balance sheet for BioNano Genomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 38.4 | 251 | 113 | 66.8 | 9.47 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.77 | 5.32 | 7.5 | 9.66 | 4.77 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 46.8 | 272 | 157 | 140 | 39.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.91 | 20.9 | 29 | 32.5 | 24.3 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 60.5 | 377 | 308 | 214 | 76.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 8.95 | 21.8 | 35.9 | 100 | 37.3 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 25.4 | 40 | 58.1 | 118 | 41.3 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 35.1 | 337 | 249 | 96.2 | 35.4 |
| Total Liabilities & Shareholders' Equity | 60.5 | 377 | 308 | 214 | 76.7 |
| Total Common Shares Outstanding |